Pseudohypoparathyroidism Type 1a
6
1
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
Theophylline for Treatment of Pseudohypoparathyroidism
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)